Cardiology in Review最新文献

Resistant hypertension (RH) is the state of uncontrolled blood pressure in the face of ostensibly optimal pharmacological intervention. It accounts for roughly one in six cases of hypertension, and is associated with more severe morbidity and mortality outcomes than is non-RH. The prevalence of RH implies a currently unmanaged pathology, which may involve the potent vasoconstrictor endothelin. Several endothelin receptor antagonists are currently marketed for pulmonary arterial hypertension, but none so far has been marketed for RH. Aprocitentan is currently in development, an endothelin receptor antagonist that effectively produces clinically significant and sustained decreases in systolic and diastolic blood pressure in the setting of RH.

Ischemic heart disease is the leading cause of mortality and morbidity in the Western world. Thus, coronary artery bypass graft is the most common cardiac procedure performed as it remains the gold standard for multiple vessel disease and left main disease. Long saphenous vein is the conduit of choice for coronary artery bypass graft as it is accessible and easy to harvest. Over the previous 4 decades, several techniques have emerged to optimize harvesting and reducing adverse clinical outcomes. The most cited techniques are open vein harvesting, no-touch technique, endoscopic vein harvesting, and standard bridging technique. In this literature review, we aim to summarize current literature for each of the 4 techniques in terms of: (A) graft patency and attrition, (B) myocardial infarction and revascularization, (C) wound infections, (D) postoperative pain, and (E) patient satisfaction.

The use of nondihydropyridine calcium channel blockers (NDCCBs) to achieve rate control in atrial fibrillation with the rapid ventricular rate (AF RVR) is not recommended in patients with comorbid heart failure with reduced ejection fraction (HFrEF) due to the concern for further blunting of contractility. However, these recommendations are extrapolated from data examining chronic NDCCB use in HFrEF patients, and comorbid AF was not analyzed. These recommendations also do not cite the hemodynamic effects or clinical outcomes of NDCCBs for acute rate control in HFrEF patients with AF RVR. It is our goal to open the discussion concerning the hemodynamic effects and safety profile of NDCCBs for acute rate control in this specific patient population. In the acute setting of AF RVR and HFrEF, there is a paucity of low-quality data on the safety and hemodynamic effects of NDCCBs, with mixed results. There has not been a clear signal toward adverse outcomes with NDCCBs, particularly for diltiazem. Data in this scenario is similarly limited for beta blockers, which provide the additional hemodynamic effect of the neurohormonal blockade, which provides a long-term mortality benefit to HFrEF patients. We support the cautious use of beta blockers as first-line therapy in clinical settings where an acute rate control strategy for AF RVR is warranted. We also support diltiazem as a reasonable second-line option, though the relative paucity of data calls for further research to validate this conclusion. Verapamil in this setting should be avoided until more data are available.

Hypoplastic left heart syndrome (HLHS) is a prevalent and lethal type of single ventricle anomaly. During early prenatal evaluations, left heart hypoplasia may be neglected due to its progressive features. It is a heterogeneous congenital heart disease with different phenotypes. Currently, there is no definite treatment for HLHS. This is in part due to its heterogeneous phenotypes that require different management. In addition, hindrances in recognizing the etiologic factors do not allow early preventive or therapeutic procedures. Phenotypic determination is fundamental to identifying the etiologic factors and therapeutic strategies. This review article introduces comprehensive information about different phenotypes and genotypes of HLHS and their novel molecular strategy. Genetic defects and flow-mediated mechanisms are the main known factors of HLHS. Recent studies reported additional data about its nonmendelian genetic origins associated with heterogeneous phenotypes. The genetic defects influence endocardium or cardiomyocyte development to yield early or late valve deformities and myocardial malformations. The new molecular therapeutic methods are essentially based on genetic etiologies. The principal therapeutic purpose is reinforcing the function of the right ventricle in patients with nonfunctional left ventricles. The ultimate desire is to create a biventricular heart in selected cases.

Hypertensive disorders in pregnancy (HDPs) are a leading cause of maternal and fetal morbidity and mortality worldwide. The pathophysiology is complex and still poorly understood but thought to involve a combination of maternal modifiable and nonmodifiable risk factors and placental changes with resultant end-organ dysfunction. Treatment of HDP involves a combination of lifestyle modification and pharmacotherapy, with differing treatment thresholds across organizations. HDP can increase maternal risk for future cardiovascular disease and has shown disparities in racial prevalence and outcomes. Additional efforts are needed to minimize the risk for future cardiovascular disease and improve racial disparities in patients facing HDP.

Mechanical compression for hemostasis posttransradial coronary angiography (CAG) or intervention is hypothesized to be more effective than manual compression owing to a more stable and continuous pressure. However, the current evidence comparing these 2 compression techniques is limited. A comprehensive search of the 3 major electronic databases-PubMed, Google Scholar, and Cochrane Library-was performed from inception to October 24, 2024, to identify relevant studies. Standardized mean difference and risk ratios (RR) with 95% confidence intervals (CIs) were pooled using the Mantel-Haenszel random effects model to calculate effect estimates. Statistical significance was set at P < 0.05. Four studies with 1235 patients undergoing transradial CAG were included [mechanical (n = 450) and manual (n = 785)]. On pooled analysis, the mechanical compression method demonstrated a significantly longer mean time to achieve hemostasis (standardized mean difference: 3.21; 95% CI: 1.71, 4.71; P < 0.0001) than the manual compression method. The risks of radial artery occlusion (RR: 1.05; 95% CI: 0.50, 2.22; P = 0.89), hematoma formation (RR: 1.86; 95% CI: 0.28, 12.40; P = 0.52), and bleeding during compression (RR: 0.23; 95% CI: 0.00, 24.81; P = 0.54) were comparable. Both types of hemostatic compression, manual and mechanical, are equally effective though mechanical compression takes significantly longer to achieve hemostasis. Further prospective randomized studies are needed to corroborate these findings.

The Food and Drug Administration (FDA) recently approved renal denervation to treat resistant hypertension. This procedure is a minimally invasive procedure that starts by placing a catheter in the renal artery. This catheter is used to send either radiofrequency heat or ultrasound waves to burn the superficial nerves surrounding the renal arteries while making certain no damage happens to the renal arteries themselves. This procedure is done after a renal angiogram to ensure patency of the renal artery. Each radiofrequency ablation will take 1-2 minutes, depending on the device used. The radiofrequency balloon generator requires one single application of the radiofrequency pulse. The radiofrequency generator that uses a catheter tube will need more than one pulse. The second approved option uses ultrasound to generate an electrical signal that is converted into ultrasound vibration, that occurs at the distal end of the catheter. This vibration heats the system around the nerves, disrupting the superficial nerves that communicate with the central nervous system. This will result in lowering the blood pressure. We will review the studies that led to FDA approval, and the current guidelines for use. The FDA now approves both devices.

Mitral regurgitation (MR) is a prevalent valvular heart disease with significant morbidity, particularly in aging populations. Management strategies for MR have evolved from traditional open-heart surgery to innovative transcatheter approaches, addressing the limitations of surgical repair in high-risk patients. Transcatheter edge-to-edge repair, exemplified by devices such as MitraClip and PASCAL, has shown efficacy in reducing MR severity, improving functional capacity, and decreasing heart failure hospitalizations in selected patients. Advances in annuloplasty and chordal repair offer minimally invasive options with promising early outcomes. Transcatheter mitral valve replacement represents the frontier of MR treatment, addressing anatomical complexities unsuitable for repair, though complications such as left ventricular outflow tract obstruction persist. Emerging data from clinical trials underscore the importance of patient selection and a multidisciplinary heart team approach. In this review, each modality is discussed concerning its indications, procedural techniques, outcomes, and associated challenges. It highlights the transformative potential of transcatheter mitral valve interventions while emphasizing the need for ongoing innovation and research to optimize outcomes and expand therapeutic options for patients with severe MR.

Tadalafil is a phosphodiesterase inhibitor currently approved for use in erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). While tadalafil's benefits in ED and BPH have been well-established for years, its benefits in PAH were identified only recently in major clinical trials, resulting in the recent approval of a single-tablet, combination therapy of tadalafil with an endothelin receptor antagonist for PAH. With Tadalafil's cardiovascular benefits in ED, BPH, and PAH, clinical researchers have begun investigating whether tadalafil's use extends to other cardiovascular diseases, especially heart failure (HF), an emerging epidemic in medicine. Recent research in animal models has demonstrated a potential benefit of tadalafil use in ischemic cardiomyopathy and HF, as numerous studies in mice and sheep demonstrated improved left ventricular function and contractility, with reduced adverse remodeling and hypertrophy. A retrospective cohort study identified that tadalafil use in patients with ED and coronary artery disease was associated with a significant decrease in the incidence of HF, acute myocardial infarction, and mortality compared with sildenafil or no treatment. However, a randomized controlled trial in patients with comorbid PAH and HF with preserved ejection fraction demonstrated no significant benefit with the use of tadalafil. Unfortunately, there is limited evidence from clinical trials investigating the impact of tadalafil in patients with HF with reduced or preserved ejection fraction without comorbid PAH. Further studies are needed on this topic to better identify whether tadalafil has a role in the prevention or treatment of HF.